Show simple item record

dc.contributor.authorGillessen, S
dc.contributor.authorAttard, G
dc.contributor.authorBeer, TM
dc.contributor.authorBeltran, H
dc.contributor.authorBossi, A
dc.contributor.authorBristow, R
dc.contributor.authorCarver, B
dc.contributor.authorCastellano, D
dc.contributor.authorChung, BH
dc.contributor.authorClarke, N
dc.contributor.authorDaugaard, G
dc.contributor.authorDavis, ID
dc.contributor.authorde Bono, J
dc.contributor.authorBorges Dos Reis, R
dc.contributor.authorDrake, CG
dc.contributor.authorEeles, R
dc.contributor.authorEfstathiou, E
dc.contributor.authorEvans, CP
dc.contributor.authorFanti, S
dc.contributor.authorFeng, F
dc.contributor.authorFizazi, K
dc.contributor.authorFrydenberg, M
dc.contributor.authorGleave, M
dc.contributor.authorHalabi, S
dc.contributor.authorHeidenreich, A
dc.contributor.authorHigano, CS
dc.contributor.authorJames, N
dc.contributor.authorKantoff, P
dc.contributor.authorKellokumpu-Lehtinen, P-L
dc.contributor.authorKhauli, RB
dc.contributor.authorKramer, G
dc.contributor.authorLogothetis, C
dc.contributor.authorMaluf, F
dc.contributor.authorMorgans, AK
dc.contributor.authorMorris, MJ
dc.contributor.authorMottet, N
dc.contributor.authorMurthy, V
dc.contributor.authorOh, W
dc.contributor.authorOst, P
dc.contributor.authorPadhani, AR
dc.contributor.authorParker, C
dc.contributor.authorPritchard, CC
dc.contributor.authorRoach, M
dc.contributor.authorRubin, MA
dc.contributor.authorRyan, C
dc.contributor.authorSaad, F
dc.contributor.authorSartor, O
dc.contributor.authorScher, H
dc.contributor.authorSella, A
dc.contributor.authorShore, N
dc.contributor.authorSmith, M
dc.contributor.authorSoule, H
dc.contributor.authorSternberg, CN
dc.contributor.authorSuzuki, H
dc.contributor.authorSweeney, C
dc.contributor.authorSydes, MR
dc.contributor.authorTannock, I
dc.contributor.authorTombal, B
dc.contributor.authorValdagni, R
dc.contributor.authorWiegel, T
dc.contributor.authorOmlin, A
dc.date.accessioned2017-07-19T14:54:48Z
dc.date.issued2018-02-01
dc.identifier.citationEuropean urology, 2018, 73 (2), pp. 178 - 211
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/715
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2017.06.002
dc.description.abstractBACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. OBJECTIVE: To present the report of APCCC 2017. DESIGN, SETTING, AND PARTICIPANTS: Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process. RESULTS AND LIMITATIONS: Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data. CONCLUSIONS: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them. PATIENT SUMMARY: The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.
dc.formatPrint-Electronic
dc.format.extent178 - 211
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectNeoplasm Staging
dc.subjectMale
dc.subjectPractice Guidelines as Topic
dc.titleManagement of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
dc.typeJournal Article
dcterms.dateAccepted2017-06-01
rioxxterms.versionofrecord10.1016/j.eururo.2017.06.002
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2018-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume73
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamTreatment Resistance
icr.researchteamOncogenetics
icr.researchteamProstate and Bladder Cancer Research
dc.contributor.icrauthorDe Bono, Johann
dc.contributor.icrauthorEeles, Rosalind
dc.contributor.icrauthorJames, Nicholas


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0